Drug Trial Radar · NCT05225415
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
May 19, 2022
Primary completion
Nov 25, 2024
Study completion Nov 25, 2024
Sponsor
- Lead sponsor
- Cognition TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute on Aging (NIA)
- First posted
- Feb 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.
Conditions
- Dementia With Lewy Bodies
Interventions
CT1812Drug
Orally administered CT1812
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 210 Days
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
University of Arizona - Health Sciences Center
Tucson, Arizona
Stanford University
Palo Alto, California
Pacific Neuroscience Institute
Santa Monica, California
University of Colorado
Aurora, Colorado
CenExel Rocky Mountain Clinical Research, LLC
Englewood, Colorado
New England Institute for Neurology and Headache (NEINH)
Stamford, Connecticut
JEM Research Institute
Atlantis, Florida
University of Miami Miller School of Medicine Comprehensive Center for Brain Health
Boca Raton, Florida
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Charter Research
Lady Lake, Florida
Renstar Medical Research
Ocala, Florida
Charter Research
Winter Park, Florida
Rush University Medical Center Section of Parkinson Disease and Movement Disorder
Chicago, Illinois
IU Health Neuroscience Center, Goodman Hall
Indianapolis, Indiana
Josephson Wallack Munshower Neurology, P.C
Indianapolis, Indiana
The University of Kansas Alzheimer's Disease Research Center
Fairway, Kansas
University of Kentucky
Lexington, Kentucky
Headlands Research Eastern Massachusetts, LLC
Plymouth, Massachusetts
Mayo Clinic
Rochester, Minnesota
Columbia University
New York, New York
UNC Department of Neurology
Chapel Hill, North Carolina
Cleveland Clinic Main Campus
Cleveland, Ohio
Ohio State University
Columbus, Ohio
Summit Headlands, LLC
Portland, Oregon
Oregon Health and Science University
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
University of Texas Southwestern
Dallas, Texas
Clinical Trial Network
Houston, Texas
University of Virginia Adult Neurology
Charlottesville, Virginia
Virginia Commonwealth University
Richmond, Virginia
Evergreen Health Research
Kirkland, Washington
Universtiy of Washington Department of Neurology
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.